Giving Voice to Cardiovocal Syndrome: A 26-Year-Old Woman With Hypophonia and Dysphagia
Stages Of Lung Cancer Listed By Type
With an Explanation of Symptom Progression
Medically reviewed by Reza Samad, MD
The stages of lung cancer range from 0 to 4 based on how advanced the cancer is. Lower numbers are less advanced and have a higher survival rate. Higher stages are more advanced and have a lower survival rate.
There are different lung cancer classification systems based on the type of cancer. Information used in staging lung cancer includes the size of the main tumor, cancer in the lymph nodes, and the spread of cancer to other areas of the body.
The lung cancer staging system lets oncologists (cancer specialists) effectively communicate with and about the patient, make accurate treatment decisions, and determine the course of the disease.
This article will review the stages of types of lung cancer, including life expectancy and survival rates at each stage. It will review the symptoms and treatment options for each lung cancer stage and how quickly it progresses.
Understanding the Stages of Lung CancerDifferent types of lung cancer use different staging systems. The two main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). There is also a type of cancerous tumor that can develop in the lungs called a carcinoid tumor. Characteristics of each include:
NSCLC is the most common type of lung cancer, making up 80% to 85% of lung cancers in the United States.
SCLC makes up 10% to 15% of lung cancer cases in the United States
Carcinoid tumors of the lungs make up just 1% to 2% of lung cancers.
Non-small cell lung cancers are staged on a traditional 0 to 4 system based on the size of the tumor, its presence in the lymph nodes, and its spread to other organs.
TNM Staging SystemMost cancers, including NSCLC, use a version of the TNM staging system. This system takes into account these three main factors:
Primary tumor size (T): How large the main tumor is
Lymph nodes (N): How many lymph nodes are positive for cancer
Metastasis (M): If the cancer has spread to other organs
The other main factor that impacts the stage of NSCLC is the type of cells the cancer has come from. The three most common kinds of non-small cell lung cancer are:
Adenocarcinomas develop from the gland cells that make mucus to lubricate the airways. It's most common in smokers or former smokers but is also the most common type of lung cancer that develops in nonsmokers. These tumors are more likely to be found before spreading to other body parts.
Squamous cell carcinomas start in the flat cells that line the airways. They're often linked to a history of smoking.
Large cell carcinomas grow and spread quickly and are more challenging to treat.
Most NSCLCs are diagnosed at stage 3 or 4. According to the National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) database, only 26% of lung and bronchus cancers are diagnosed early, with more than half (53%) of cases found after it has already spread to other body parts (metastasized).
Staging and Treatment of Small Cell Lung CancerSmall cell lung cancers use a different staging system. This system only has two stages.
Limited SCLC is on just one side of the chest but can be present in both the lung and lymph nodes. These cancers are confined to an area small enough to be treated with radiation through just one port.
About one-third of people with SCLC are classified as limited-stage. They will typically benefit from more aggressive treatment options like chemotherapy combined with radiation to try to cure the cancer.
Extensive SCLC is typically spread over a larger area—widespread within one side of the chest or on both sides. The cancer may also have spread to lymph nodes above the collar bone, on the other side of the chest, or in the middle of the chest. Cancer may have spread to the fluid around the lung or other body parts and organs.
Extensive-stage SCLC is more advanced, so treatments aim to control the spread of cancer instead of cure it. This would typically involve chemotherapy alone. Two-thirds of small cell lung cancers are classified as extensive stage.
Staging Carcinoid Tumors of the LungCarcinoid lung cancers may grow very slowly and are less likely to spread to other body parts than other lung cancers. The staging system used for lung carcinoid tumors is a version of the TNM staging system published by the American Joint Committee on Cancer (AJCC) in 2018, includes:
Occult (hidden) cancer is when the main tumor can't be found and hasn't spread.
Stage 0 hasn't spread beyond the top layers of the airways.
Stage 1 cancers, including 1A (1A1, 1A2, 1A3) and 1B, carcinoid lung cancers, are smaller and have not spread beyond the lungs.
Stage 2A and 2B carcinoid lung cancers are larger than stage 1 or have spread to a lymph node.
Stage 3A, 3B, and 3C carcinoid lung tumors are even larger, or they have spread to multiple lymph nodes or other chest structures or the other side of the chest.
Stage 4A and 4B cancers have spread out of the lung to the other lung, the fluid around the lungs or heart, or outside of the chest.
Stage 0 non-small cell lung cancer is the most curable stage of this common lung cancer. Stage 0 is when cancer cells are found only in the topmost layer of cells in the airway lining. They haven't spread deeper into the airway nor are they found in any lymph nodes or other body parts.
Early lung cancers typically have very few symptoms. Most lung cancers do not have symptoms until they spread outside the lungs. This makes it challenging to catch lung cancers early.
Treatment for stage 0 NSCLC typically involves surgery without chemotherapy or radiation. Usually, the small section of the lung that is cancerous is removed using a segmentectomy (removal of a segment of the lung) or wedge resection (removal of a wedge-shaped area of the lung). These treatments should be enough to cure stage 0 NSCLC.
Alternatives to surgery include photodynamic therapy (a light-sensitizing drug and bright light is used to kill cancer cells), laser therapy, or brachytherapy (internal radiation).
It is not often that lung cancers are caught at stage 0. If they are, it's usually because you're getting scanned for another reason or getting screening for being high risk. If it is completely removed, stage 0 NSCLC is curable and should not recur, indicating a high survival rate is likely.
Stage 1 NSCLCStage 1 non-small cell lung cancer is divided into the following stages:
Stage 1A (1A1, 1A2, 1A3) tumors are smaller than 3 centimeters (cm) and haven't invaded deeper lung tissue. Most often, they haven't reached the lung membranes or central airways or spread anywhere else.
Stage 1B NSCLCs are either 3 to 4 cm, have grown into the central airway or membranes, or partially block the airway.
Stage 1 NSCLC is typically treated with surgery to remove the area of the lung with the primary tumor. The surgeon will also check the lymph nodes and the space between the lungs for cancer.
Certain factors may make stage 1 NSCLC more likely to return after surgery. In these cases, the person may get additional treatment with chemotherapy and possibly immunotherapy after surgery.
If analysis of the removed portion of the lung after surgery suggests that there may have been cancer left behind, you may need another surgery or radiation.
Immunotherapy with Opdivo (nivolumab) is another option for larger tumors. It is used along with chemotherapy before surgery. Additional therapy after surgery might be needed depending on what is found at the time of surgery.
People with serious health problems who can't have surgery may get radiation therapy, including stereotactic body radiation therapy (which delivers precise and intense doses of radiation to the cancer site) or radiofrequency ablation treatment (radio waves apply heat to destroy tissues).
About 26% of adenocarcinomas of the lung and bronchus are found at the localized stage. The localized stage is the National Cancer Institute's SEER database equivalent to stage 1 or stage 0 cancers. These cancers have not spread beyond the tissue or organ they started in (the primary site).
Survival Rates for Localized NSCLC and Lung AdenocarcinomaThe five-year relative survival rate for people diagnosed with localized lung adenocarcinoma between 2013 and 2019 was 73.3%. That means nearly 3 out of every 4 people who were diagnosed with stage 1 or 0 adenocarcinoma NSCLC during this period were still alive five years later. For all NSCLCs, the survival rate for localized cancers is 65%.
Stage 2 NSCLCStage 2 non-small cell lung cancer is larger tumors that may have spread within the lung area or to one or more lymph nodes, as follows:
Stage 2A NSCLC tumors are 4 to 5 cm across. They've either grown into the central airway and the membranes around the lungs or they partially block the airway.
Stage 2B NSCLC tumors are either 5 to 7 cm or have spread to at least one lymph node on the same side of the chest. A tumor may also have grown into the central airway, the membranes around the lungs, or partially blocked the airway.
Most early-stage lung cancers do not have symptoms. Lung cancer symptoms that may crop up for stage 2 and other early-stage cancers include:
Cough that sticks around and continues to get worse
Bloody or rust-colored spit or phlegm from a cough
Pain in the chest when deep breathing, coughing, or laughing
Hoarseness
Lack of hunger
Losing weight without a reason
Loss of breath
Tiredness or weakness
Recurrent bronchitis or pneumonia
Wheezing that wasn't present before
Treatment for stage 2 NSCLC includes surgery, which might consist of removing the whole lung and any lymph nodes that may have cancer.
After surgery, the tissues removed are checked for cancer. If some were left behind, you may need another surgery and then treatment with a combination of chemotherapy, immunotherapy, and radiation.
Chemo and/or immunotherapy may be recommended after surgery even if they believe all of the cancer was removed.
For larger tumors, treatments before surgery may include immunotherapy with Opdivio and chemotherapy. People who can't have surgery may only get radiation.
Stage 3 NSCLCStage 3 non-small cell lung cancers have spread to more lymph nodes and further areas within the chest cavity. They may also be larger. These stages include:
Stage 3A lung tumors may still be small but have spread to lymph nodes around where the windpipe splits or in the space between the lungs on the same side of the lung.
Stage 3B lung tumors are a bit larger and may have also grown into the central airway and the membranes around the lungs or they partially block the airway.
Stage 3C lung tumors are large and spread to other structures of the lungs, potentially with two or more nodules and lymph nodes near the collarbone or on the other side of the body. They may also have infringed on the heart or other structures in the chest, like the esophagus, diaphragm, or spine.
Treatment of stage 3 lung cancers includes a mix of radiation, chemotherapy, and surgery. Immunotherapy with Opdivo, Keytruda (pembrolizumab), Imfinzi (durvalumab), or Libtayo (cemiplimab), or targeted treatment with Tagrisso (osimertinib) may be an option for some stage 3 lung cancers.
These cancers can be hard to treat, so taking part in a clinical trial of newer treatments may be a good option for some people.
About 19% of adenocarcinomas of the lung and bronchus are found at the regional stage. The regional stage is the National Cancer Institute's SEER database equivalent to stage 2 or stage 3 cancers. These cancers have spread to lymph nodes and other tissues within the organ they developed in but have not spread to far reaches of the body.
Survival Rates for Regional NSCLCThe five-year survival rate for people diagnosed with regional lung adenocarcinoma between 2013 and 2019 was 46.4%. That means about half of people who were diagnosed with stage 2 or stage 3 adenocarcinoma NSCLC during this period were still alive five years later. For all NSCLCs, the survival rate for regional cancers is 37%.
Stage 4 NSCLCStage 4 non-small cell lung cancers are the most advanced and have the worst survival rate. Stage 4 lung cancers are challenging to cure. These cancers can be any size and may be present in any number of lymph nodes in any part of the body.
The defining trait of stage 4 lung cancers is that they've spread beyond the lungs to other organs. They include:
Stage 4A lung cancers are either in both lungs, the fluid around the lungs, or the fluid around the heart. Or it may have spread outside the chest to the brain, liver, bones, or another organ.
Stage 4B lung cancers have become tumors in other parts of the body, including in faraway lymph nodes or organs.
When lung cancer spreads to other parts of the body, it leads to more detectable symptoms, such as:
Lung cancer in the bones may cause bone pain in the back or hips.
Lung cancer in the brain can cause headaches, weakness or numbness of an arm or leg, dizziness, balance problems, or seizures.
Lung cancer in the liver can cause the eyes and skin to turn yellow.
Lung cancer that has spread to the visible lymph nodes in the neck or above the collarbone can cause them to swell up.
Treatment for stage 4 lung cancers can include surgery, chemotherapy, targeted therapy, multiple immunotherapy options, radiation therapy, photodynamic therapy, or laser therapy. These treatments are intended to help you live longer and relieve symptoms.
Genetic analysis of the tumor before any treatment can refine treatment choices, including the use of targeted treatments, including:
Lumakras (sotorasib) or Krazati (adagrasib) for a KRAS G12C gene change
Anaplastic lymphoma kinase (ALK) inhibitors for tumors that have the ALK gene change
Epidermal growth factor receptor (EGFR) inhibitors for changes in the EGFR gene
Xalkori (crizotinib), Rozlytrek (entrectinib), or Zykadia (ceritinib) for changes in the ROS1 gene
Tafinlar (dabrafenib) with Mekinist (trametinib) for a change in the BRAF gene
Retevmo (selpercatinib) or Gavreto (trametinib) for changes in the RET gene
Tabrecta (lapatinib) or Tepmetko (lapatinib) for changes in the MET gene
Vitrakvi (larotrectinib) or Rozlytrek (entrectinib) for a change in the NTRK gene
About 51.9% of adenocarcinomas of the lung and bronchus are found at the distant stage. The "distant" stage is the National Cancer Institute's SEER database equivalent to stage 4 cancers. These cancers have spread to far away lymph nodes and other organs.
Survival Rates for Distant NSCLCThe five-year survival rate for people diagnosed with distant lung adenocarcinoma between 2013 and 2019 was 11%. That means 11 out of 100 people who were diagnosed with stage 4 adenocarcinoma NSCLC during this period were still alive five years later. For all NSCLCs, the survival rate for distant cancers is 9%.
Related: Where Does Lung Cancer Spread?
Factors Influencing Success of Early-Stage TreatmentEarly-stage lung cancer usually refers to stages 1, 2, and 3A NSCLC and limited-stage SCLC.
Factors influencing the success of these treatments include the tumor's location, how much it has grown or spread, and where it is located in the lung—other factors like proteins the cancer is making or the genetic changes that may also play a role.
What options are suitable for your cancer depends a lot on the size of the tumor, its location, what lymph nodes it has spread to, how healthy you are, and how treatment progresses.
Lung Cancer Progression VariesHow quickly cancer moves from one stage to the next depends on a variety of factors and varies from person to person. There are several ways in which lung cancer progresses.
One important factor in lung cancer progression is the type of cancer. Small cell lung cancers can spread early, even from a very small primary tumor. Non-small cell cancers vary in their growth rates.
Factors Influencing Success of Late Stage TreatmentTreatment for late-stage lung cancer, including stage 3B and stage 4 lung cancers, is determined by multiple factors. The treatment for your cancer is likely to be determined by your desires as much as where and how far the cancer has spread, whether the cancer cells have certain gene or protein changes, and your overall health.
Your health, treatment goals, and how you react to treatments play a significant role in what treatments are tried for late-stage lung cancer.
SummaryCancer doctors classify lung cancer from stages 0 to 4 based on how large it is and how it has spread. Types of lung cancer use different staging systems. An oncologist determines the cancer's stage by its size, lymph nodes, and spread. Also significant are the type of cancer and any protein or gene changes.
Non-small cell lung cancers (NSCLC) include adenocarcinomas, squamous, and large cell carcinomas. Oncologists stage small cell lung cancers (SCLC) as a limited or extensive stage. Carcinoid tumors of the lung follow a basic TNM staging system based on tumor size, lymph node involvement, and metastasis.
The distinct stages of NSCLC have varying survival rates and treatment approaches. A surgeon could cure stage 0 NSCLC. But an oncologist would treat advanced NSCLC with a mix of:
Factors influencing treatment success include where the tumors are and how early they're found.
Read the original article on Verywell Health.
View comments
Potential New Treatment For Pulmonary Neuroendocrine Tumors
The Organoid Group (Hubrecht Institute) and the Rare Cancers Genomics Team (IARC/WHO) found a way to grow samples of different types of neuroendocrine tumors (NETs) in the lab. While generating their new model, the researchers discovered that some pulmonary NETs need the protein EGF to be able to grow. These types of tumors may therefore be treatable using inhibitors of the EGF receptor. The results were published in Cancer Cell on 11 December 2023.
Neuroendocrine tumors
Neuroendocrine tumors (NETs) are relatively rare tumors that can be slow-growing. However, some NETs can be aggressive and hard to treat. It is not yet possible to predict which tumors will become aggressive. There are very few models to study NETs in the lab, which limits research into this type of tumor.
New disease model
Researchers from the Organoid Group (Hubrecht Institute) and the Rare Cancers Genomics Team (IARC/WHO) therefore set out to develop new models to study NETs. They derived cells from patients with NETs and were able to culture them into 3D structures called organoids. These organoids mimic the behavior of actual NETs and can therefore be used to study this type of tumor in the lab. The new model is the first organoid model of the disease.
Growth factor
While generating the organoids, the researchers found that some pulmonary NETs need a protein called the Epidermal Growth Factor (EGF) to grow. "If we inhibit the receptor for EGF, some organoids die. Apparently, these organoids are dependent on EGF for their survival," says Talya Dayton, co-first author on the paper published in Cancer Cell. "We need further research to confirm our findings, but this may indicate that patients with EGF-dependent NETs could be treated with inhibitors of the EGF receptor." Inhibitors of the EGF receptor are already a course of treatment for other types of tumors.
Aggressive tumors
Tumors are usually thought to be independent of growth factors. That some NETs turn out to be dependent on the growth factor EGF is therefore surprising. "We think that their EGF-dependence might explain, in part, why some of these tumors grow slowly. We also think this might mean that one of the ways in which NETs can become aggressive is by becoming growth-factor independent. If they no longer need the growth factor, their growth may accelerate" Dayton explains.
Potential new therapy
The newly developed model for NETs provides a new way to study the disease in the lab. Dayton: "This allows us and other scientists to understand the biology of these tumors so we can hopefully find effective therapies." Although further research is needed, the model already points to a new route of treatment for patients with pulmonary NETs.
Fibrosis And Carcinoid Syndrome: From Causation To Future Therapy
Modlin, I. M., Shapiro, M. D. & Kidd, M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum. Pathol. 35, 1440–1451 (2004).
Kloppel, G., Perren, A. & Heitz, P. U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. NY Acad. Sci. 1014, 13–27 (2004).
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N. & Shapiro, M. D. Current status of gastrointestinal carcinoids. Gastroenterology 128, 1717–1751 (2005).
Eriksson, B. Et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8–19 (2008).
Modlin, I. M., Shapiro, M. D. & Kidd, M. Carcinoid tumors and fibrosis: an association with no explanation. Am. J. Gastroenterol. 99, 2466–2478 (2004).
Morgan, J. G., Marks, C. & Hearn, D. Carcinoid tumors of the gastrointestinal tract. Ann. Surg. 180, 720–727 (1974).
Kidd, M., Shapiro, M. D. & Lye, K. D. Connective tissue growth factor (CTGF) is overexpressed in ileal carcinoids. Presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, January 22–24, San Francisco, California, USA (2004).
Hellman, P. Et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J. Surg. 26, 991–997 (2002).
Cai, Y. C. Et al. Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-α. Am. J. Surg. Pathol. 21, 1373–1377 (1997).
Kottra, J. J. & Dunnick, N. R. Retroperitoneal fibrosis. Radiol. Clin. North Am. 34, 1259–1275 (1996).
Dev., S., al Dujaily, S. & Subbuswamy, S. G. A case of ureteric obstruction, retroperitoneal fibrosis, and carcinoid tumour. Postgrad. Med. J. 75, 38–40 (1999).
Morand, J. J. Et al. Edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature [French]. Rev. Med. Interne. 18, 388–395 (1997).
Nelson, D. R., Stachura, M. E. & Dunlap, D. B. Ileal carcinoid tumor complicated by retroperitoneal fibrosis and a prolactinoma. Am. J. Med. Sci. 296, 129–133 (1988).
Scott, J., Foster, R. & Moore, A. Retroperitoneal fibrosis and nonmalignant ileal carcinoid. J. Urol. 138, 1435 (1987).
Gupta, A., Saibil, F., Kassim, O. & McKee, J. Retroperitoneal fibrosis caused by carcinoid tumour. Q. J. Med. 56, 367–375 (1985).
Moss, S. F. Et al. Pleural involvement in the carcinoid syndrome. Q. J. Med. 86, 49–53 (1993).
Tamagno, G., Goglia, U., Villa, G. & Murialdo, G. Lung fibrosis in carcinoid syndrome. Intern. Med. 46, 425–426 (2007).
Seo, J. W., Im, J. G., Kim, Y. W., Kim, J. H. & Sheppard, M. N. Synchronous double primary lung cancers of squamous and neuroendocrine type associated with cryptogenic fibrosing alveolitis. Thorax 46, 857–858 (1991).
Miller, R. R. & Muller, N. L. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am. J. Surg. Pathol. 19, 653–658 (1995).
Kucuk, O. Et al. Lower extremity vasospasm associated with ischemic neuropathy, dermal fibrosis, and digital gangrene in a patient with carcinoid syndrome. Cancer 62, 1026–1029 (1988).
Bell, H. K., Poston, G. J., Vora, J. & Wilson, N. J. Cutaneous manifestations of the malignant carcinoid syndrome. Br. J. Dermatol. 152, 71–75 (2005).
Ratnavel, R. C., Burrows, N. P. & Pye, R. J. Scleroderma and the carcinoid syndrome. Clin. Exp. Dermatol. 19, 83–85 (1994).
Thorson, A., Biorck, G., Bjorkman, G. & Waldenstrom, J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am. Heart J. 47, 795–817 (1954).
Ferrans, V. J. & Roberts, W. C. The carcinoid endocardial plaque; an ultrastructural study. Hum. Pathol. 7, 387–409 (1976).
Norheim, I. Et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann. Surg. 206, 115–125 (1987).
Lundin, L., Norheim, I., Landelius, J., Oberg, K. & Theodorsson-Norheim, E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77, 264–269 (1988).
Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am. J. Cardiol. 101, 378–381 (2008).
Bhattacharyya, S., Davar, J., Dreyfus, G. & Caplin, M. E. Carcinoid heart disease. Circulation 116, 2860–2865 (2007).
Howard, R. J. Et al. Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation 66, 1059–1065 (1982).
Zanettini, R. Et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39–46 (2007).
Bader, T. R., Semelka, R. C., Chiu, V. C., Armao, D. M. & Woosley, J. T. MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J. Magn. Reson. Imaging 14, 261–269 (2001).
Woodard, P. K., Feldman, J. M., Paine, S. S. & Baker, M. E. Midgut carcinoid tumors: CT findings and biochemical profiles. J. Comput. Assist. Tomogr. 19, 400–405 (1995).
Pantongrag-Brown, L., Buetow, P. C., Carr, N. J., Lichtenstein, J. E. & Buck, J. L. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am. J. Roentgenol. 164, 387–391 (1995).
Horton, K. M., Lawler, L. P. & Fishman, E. K. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 23, 1561–1567 (2003).
Levy, A. D., Rimola, J., Mehrotra, A. K. & Sobin, L. H. From the archives of the AFIP: benign fibrous tumors and tumorlike lesions of the mesentery: radiologic–pathologic correlation. Radiographics 26, 245–264 (2006).
Coulier, B. Et al. Carcinoid tumor of the small intestine: MDCT findings with pathologic correlation. JBR-BTR 90, 507–515 (2007).
Lesurtel, M., Soll, C., Graf, R. & Clavien, P. A. Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives. Cell. Mol. Life Sci. 65, 940–952 (2008).
Barnes, N. M. & Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083–1152 (1999).
Kim, D. Y. & Camilleri, M. Serotonin: a mediator of the brain–gut connection. Am. J. Gastroenterol. 95, 2698–2709 (2000).
Launay, J. M. Et al. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J. Biol. Chem. 271, 3141–3147 (1996).
Nebigil, C. G., Launay, J. M., Hickel, P., Tournois, C. & Maroteaux, L. 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: crosstalk with tyrosine kinase pathways. Proc. Natl Acad. Sci. USA 97, 2591–2596 (2000).
Mason, J. W., Billingham, M. E. & Friedman, J. P. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 56, 889–890 (1977).
Connolly, H. Et al. Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. 337, 581–588 (1997).
Antonini, A. & Poewe, W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 6, 826–829 (2007).
Jagroop, I. A. & Mikhailidis, D. P. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 11, 161–165 (2000).
Gustafsson, B. I. Et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111, 1517–1522 (2005).
Mekontso-Dessap, A. Et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113, 81–89 (2006).
Musunuru, S., Carpenter, J. E., Sippel, R. S., Kunnimalaiyaan, M. & Chen, H. A mouse model of carcinoid syndrome and heart disease. J. Surg. Res. 126, 102–105 (2005).
Wang, B. Et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 293, H1282–H1290 (2007).
Ruddell, R. G. Et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am. J. Pathol. 169, 861–876 (2006).
Caplin, M. E. Et al. Carcinoid tumour. Lancet 352, 799–805 (1998).
Kulke, M. H. & Mayer, R. J. Carcinoid tumors. N. Engl. J. Med. 340, 858–868 (1999).
Jian, B. Et al. Serotonin mechanisms in heart valve disease I: serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am. J. Pathol. 161, 2111–2121 (2002).
Moller, J. E. Et al. Factors associated with progression of carcinoid heart disease. N. Engl. J. Med. 348, 1005–1015 (2003).
Nilsson, C. L., Brodin, E. & Ekman, R. Substance P and related peptides in porcine cortex: whole tissue and nuclear localization. J. Chromatogr. A 800, 21–27 (1998).
Chaudhry, A., Funa, K. & Oberg, K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 32, 107–114 (1993).
Waltenberger, J. Et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am. J. Pathol. 142, 71–78 (1993).
Kidd, M. Et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J. Gastroenterol. 13, 5208–5216 (2007).
Lal, A. & Chen, H. Treatment of advanced carcinoid tumors. Curr. Opin. Oncol. 18, 9–15 (2006).
Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am. J. Cardiol. 102, 938–942 (2008).
Ohrvall, U. Et al. Method for dissection of mesenteric metastases in midgut carcinoid tumors. World J. Surg. 24, 1402–1408 (2000).
Howell, S. B. Et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97, 845–851 (1982).
Moertel, C. G., Kvols, L. K. & Rubin, J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67, 33–36 (1991).
Robertson, J. I. Carcinoid syndrome and serotonin: therapeutic effects of ketanserin. Cardiovasc. Drugs Ther. 4 (Suppl. 1), S53–S58 (1990).
Noppen, M., Jacobs, A., Van Belle, S., Herregodts, P. & Somers, G. Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome. Br. Med. J. (Clin. Res. Ed.) 296, 682–683 (1988).
Wymenga, A. N., de Vries, E. G., Leijsma, M. K., Kema, I. P. & Kleibeuker, J. H. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur. J. Cancer 34, 1293–1294 (1998).
Jacobsen, M. B. Ondansetron in carcinoid syndrome. Lancet 340, 185 (1992).
Hauso, O. Et al. Long-term serotonin effects in the rat are prevented by terguride. Regul. Pept. 143, 39–46 (2007).
Ciccarelli, E., Touzel, R., Besser, M. & Grossman, A. Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil. Steril. 49, 589–594 (1988).
Greenblatt, D. Y. Et al. Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12, 942–951 (2007).
Kunnimalaiyaan, M. & Chen, H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17, 139–142 (2006).
Brown, P., Pappas, C., Frazier, K., Turnage, A. & Liu, Q. LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome. [Abstract C16] Presented at the 6th Annual Conference of the European Neuroendocrine Tumor Society: 2009 March 5–7, Granada, Spain.
Comments
Post a Comment